{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:20:20Z","timestamp":1772504420174,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>The cornerstone treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) in children is a combination of therapeutic plasma exchange (TPE), corticosteroids, and rituximab. Caplacizumab is an anti-von Willebrand factor (VWF) NANOBODY molecule approved as a frontline therapy of iTTP for adults and children aged \u226512 years. Using caplacizumab in children aged &amp;lt;12 years remains a gray area based on recommendations but with no marketing authorization. We report the first case of a pediatric patient with iTTP successfully treated with a caplacizumab dose adjustment of 5\u2005mg daily based on ADAMTS13 activity. We also review all published cases of iTTP in children aged &amp;lt;12 years treated with caplacizumab. This is a 7-year-old girl with clinical thrombotic microangiopathy, in the absence of diarrhea and kidney injury. With a French score of 2 and a PLASMIC score of 7 (high risk), the diagnosis of TTP was suspected and later confirmed by severely low ADAMTS13 activity (&amp;lt;5%). Immune-mediated TTP was distinguished from the congenital one due to the presence of a functional ADAMTS13 inhibitor. Daily TPE and intravenous corticosteroids were started on day 0 (D0). Rituximab was added on D4, and due to refractoriness under daily TPE, we considered off-label administration of caplacizumab from D12. A clinical answer, with a significant increase in the platelet count, was observed within 48\u2005h. A complete ADAMTS13 recovery was reached on D62. No major adverse events were observed during the treatment. She was discharged from the hospital over 3 months ago with a platelet count still within normal ranges. In the literature, we identified a total of four case reports describing five iTTP patients aged &amp;lt;12 years treated with caplacizumab, with a 100% success and tolerability rate. These published data attest to the efficacy and safety of the systematic use of caplacizumab and rituximab as frontline therapy in pediatric iTTP under 12 years of age. Therefore, prospective data are needed to support commercial authorization of caplacizumab in this subpopulation. Close monitoring of ADAMTS13 activity is particularly of interest among children to limit the number of caplacizumab injections.<\/jats:p>","DOI":"10.3389\/fped.2024.1448801","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T18:54:11Z","timestamp":1724352851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Lara","family":"Chavaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Cimasoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/jth.15194","article-title":"Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?","volume":"19","author":"Picod","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e28949","DOI":"10.1002\/pbc.28949","article-title":"Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children","volume":"68","author":"Siddiqui","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.24339","article-title":"Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: a systematic review","volume":"91","author":"Thejeel","year":"2016","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jcph.1991","article-title":"Caplacizumab model-based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura","volume":"62","author":"Bergstrand","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1182\/blood.2022018847","article-title":"Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era","volume":"141","author":"Prasannan","year":"2023","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00277-021-04740-4","article-title":"Off-label caplacizumab as add-on therapy in a 9-year-old boy with refractory aTTP","volume":"101","author":"Veltroni","year":"2022","journal-title":"Ann Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e30390","DOI":"10.1002\/pbc.30390","article-title":"2023 ASPHO conference paper and poster index","volume":"70","author":"Graciaa","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2023.06.002","article-title":"Immature platelet dynamics in management of protracted response to therapy of a young pediatric patient with immune-mediated thrombotic thrombocytopenic purpura","volume":"228","author":"Maitta","year":"2023","journal-title":"Thromb Res"},{"key":"B22","article-title":"Researcher View | Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP) | ClinicalTrials.gov","year":""}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1448801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T18:54:13Z","timestamp":1724352853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1448801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":22,"alternative-id":["10.3389\/fped.2024.1448801"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1448801","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"article-number":"1448801"}}